Linaclotide
Brand name: Linzess
Rank #27 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$639.4M
Total Cost
823,023
Total Claims
$639.4M
Total Cost
23,483
Prescribers
$777
Cost per Claim
133,250
Beneficiaries
1,181,116
30-Day Fills
$27K
Avg Cost/Provider
35
Avg Claims/Provider
Share of Medicare Part D Spending
0.23%
of total Medicare Part D spending
$639.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $639.4M total
🔎 Data Overview
Ranked #27 out of 500 drugs tracked by total cost. Linaclotide represents a significant portion of Medicare drug spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Linaclotide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Mikhail Korogluyev | Osteopathic Manipulative Medicine | Brooklyn, NY | 1,288 | $730K |
| 2 | Gopal Narasimhan | Internal Medicine | New York, NY | 1,051 | $694K |
| 3 | Vlad Nusinovich | Internal Medicine | West Hollywood, CA | 1,074 | $596K |
| 4 | Anahita Anderson | Nurse Practitioner | Jackson, TN | 548 | $595K |
| 5 | Arutyun Topsakalyan | General Practice | Glendale, CA | 970 | $563K |
| 6 | Yuriy Pertsovsky | Gastroenterology | Brooklyn, NY | 970 | $550K |
| 7 | Ramesh Gupta | Gastroenterology | Fair Lawn, NJ | 435 | $538K |
| 8 | Sergei Chekov | Internal Medicine | Philadelphia, PA | 926 | $528K |
| 9 | Mark Azbel | Internal Medicine | Brooklyn, NY | 919 | $526K |
| 10 | Oleg Volchonok | Gastroenterology | Philadelphia, PA | 846 | $506K |
| 11 | Tu Truong | Internal Medicine | San Diego, CA | 459 | $502K |
| 12 | Yervand Set Agayan | Family Practice | Glendale, CA | 854 | $492K |
| 13 | Kelvin Mai | Internal Medicine | Santa Ana, CA | 664 | $480K |
| 14 | Hoover Royals | Family Practice | Dover, NC | 877 | $479K |
| 15 | Min Wong | Internal Medicine | Brooklyn, NY | 444 | $467K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology